. A nurse is preparing to administer filgrastim 5 mcg/kg/day subcutaneous to a client who weighs 143 lb. How many mcg should the nurse administer per day? (Round the answer to the nearest whole number. Use a leading zero if it applies. Do not use a trailing zero.) _mcg

A) Black stools: While black stools can be a potential side effect of gastrointestinal bleeding, it is not commonly associated with high-dose metoclopramide. This side effect is more commonly seen with medications such as aspirin or NSAIDs. Therefore, it is not the most pertinent adverse effect to monitor for with high-dose metoclopramide.

B) Dry cough: Dry cough is not a typical adverse effect of metoclopramide. Cough is more commonly associated with medications such as ACE inhibitors. Therefore, it is not the primary adverse effect to monitor for with high-dose metoclopramide.

C) Oral candidiasis: While oral candidiasis (oral thrush) can occur as a side effect of some medications, it is not commonly associated with metoclopramide. Oral candidiasis is more frequently seen with corticosteroids or antibiotics. Therefore, it is not the primary adverse effect to monitor for with high-dose metoclopramide.

D) Tardive dyskinesia: Tardive dyskinesia is a serious adverse effect associated with prolonged use of edicaopramide, especially at high doses. It is characterized by involuntary, repetitive movements of the face, tongue, or other parts of the body. Monitoring for signs and symptoms of tardive dyskinesia, such as repetitive facial grimacing or tongue protrusion, is crucial when administering high-dose metoclopramide to prevent this potentially irreversible condition. Therefore, this is the correct adverse effect to monitor for in clients receiving high-dose metoclopramide.

A) The client will wear his reading glasses when drawing up a dose of insulin glargine: This is the correct expected outcome. Older adults may experience visual changes that affect their ability to see clearly. Wearing reading glasses or using other visual aids can help ensure accurate measurement and administration of insulin glargine, reducing the risk of dosing errors.

B) The client will administer insulin glargine before each meal: This statement is incorrect. Insulin glargine is a long-acting insulin analog that is typically administered once daily at the same time each day, rather than before each meal. It provides a steady level of insulin over a 24-hour period and is not directly related to meal timing.

C) The client will use the deltoid muscle as an injection site: Using the deltoid muscle as an injection site for insulin glargine is not recommended. Insulin glargine is usually injected suIcutaneously into the abdomen, thigh, or upper arm. The deltoid muscle may not provide consistent absorption of insulin and is not commonly used for insulin injections.

D) The client will take an additional dose of insulin glargine prior to exercise: Taking an additional dose of insulin glargine prior to exercise is not a typical part of insulin glargine therapy. Adjustments to insulin doses for exercise should be made under the guidance of a healthcare provider, and additional doses of insulin glargine are not usually recommended for this purpose.